Zimbabwe blames sanctions for collapse

20 March 2006

Zimbabwe's Ministry of Health and Child Welfare has admitted that shortages of drug supplies - a consequence of economic sanctions against the southern African country - are endangering the lives of thousands of people, many of whom are resorting to sharing anti-retroviral drugs.

Edwin Muguti, Zimbabwe's Deputy Minister of Health and Child Welfare, testified at hearings of the country's Parliamentary Portfolio Committee on Health about the desperate situation for many people. He told the Harare Herald, "sanctions kill," adding that "it is not, and never has been, a question of unwillingness on our part to supply anti-retrovirals. But it is a question of availability; it is a question of money. We are unable as a country to supply all the goods and services that we should be supplying." An estimated 25,000 people are dependent on the state-funded HIV/AIDS drug program.

Other priorities for Global Fund money

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight